Business Context and Reporting Period
Company: CLEARONE INC (CLRO)
Filing Type: Form 10-Q
Period Ended: June 30, 2026
Status: Smaller Reporting Company; Non-Accelerated Filer
Following the October 24, 2025, sale of substantially all operating assets and intellectual property to Biamp Systems, LLC, ClearOne no longer manufactures or sells products. Continuing operations are limited to fulfilling legacy warranty obligations, maintaining public-company compliance, collecting receivables, and pursuing strategic alternatives. On July 1, 2026, the Company entered into a Merger Agreement to combine with Cortigent, Inc. (surviving as a subsidiary of ClearOne, which will be renamed Cortigent Holdings, Inc.).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Revenue (Continuing) | $0 | $0 | $0 |
| Revenue (Discontinued) | $0 | $0 | $4,229 |
| Net Loss (Total) | $(914) | $(1,401) | $(7,406) |
| Net Loss (Continuing Ops) | $(919) | $(1,769) | $(2,019) |
| Net Income (Discontinued Ops) | $5 | $368 | $(5,387) |
| Cash & Cash Equivalents | $75 | $75 | $220 (Dec 31, 2025) |
| Restricted Cash | $447 | $447 | $519 (Dec 31, 2025) |
| Total Liabilities | $1,371 | $1,371 | $3,013 (Dec 31, 2025) |
| Shareholders' Equity | $(381) | $(381) | $(714) (Dec 31, 2025) |
Debt: As of June 30, 2026, the Company had a short-term note payable of $500 to a related party (First Finance). A subsequent tranche of $500 was received on July 16, 2026, bringing the total facility to $1,000. The note bears 11% interest and matures December 30, 2026.
Material Changes vs. Prior Period
- Cessation of Operations: Revenue from continuing operations is $0, reflecting the completion of the Asset Sale in October 2025. All historical product revenue is now classified as discontinued operations.
- Discontinued Operations: The six-month 2026 period shows a net income of $368 from discontinued operations, compared to a net loss of $(5,387) in the prior year. This improvement is primarily due to a $763 income tax benefit from the release of uncertain tax positions (statute of limitations lapse) and the absence of operating losses from the disposed business.
- Operating Expenses: General and administrative expenses for continuing operations decreased 14% year-over-year (six months) to $1,629, reflecting reduced corporate infrastructure and headcount, partially offset by legal and advisory fees related to the Merger.
- Lease Termination: The Company terminated all operating leases by April 2026, resulting in $0 operating lease liabilities as of June 30, 2026, compared to $513 at year-end 2025.
Guidance, Outlook, Risks, and Unusual Items
Going Concern: The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern within one year. The Company has no revenue-generating operations and relies on the $1.0 million related-party loan and the successful completion of the Merger and a concurrent $10M-$15M financing to fund operations.
Merger and Financing:
- Merger: ClearOne will merge with Cortigent, Inc. The transaction is expected to be a reverse recapitalization. Vivani Medical, Inc. (Cortigent's parent) will control the combined company.
- Financing: A best-efforts offering of units (stock + warrants) is planned to raise $10M-$15M. Completion of this financing is a condition to the Merger.
- Nasdaq Listing: Nasdaq has determined the Merger constitutes a "Change of Control," requiring the post-transaction entity to meet initial listing standards. Failure to do so could result in delisting.
Unusual Items:
- Tax Benefit: A $763 tax benefit in discontinued operations resulted from the expiration of statutes of limitations on uncertain tax positions.
- Preferred Stock Redemption: Class A Redeemable Preferred Stock was redeemed at par value ($2 total) in April 2026; holders received no distribution of Asset Sale proceeds.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of the Form S-1 registration statement effectiveness and the completion of the $10M-$15M financing, both of which are mandatory for the Merger to close.
- Nasdaq Compliance: Confirm whether the post-transaction entity has satisfied Nasdaq's initial listing requirements following the Change of Control determination.
- Liquidity Runway: Assess the sufficiency of the $1.0 million related-party loan (maturing Dec 2026) to cover operating costs if the Merger or Financing is delayed or terminated.
- Dilution Impact: Review the pro forma capitalization, noting that the Merger consideration and advisor shares represent approximately 82% of the pro forma common stock, significantly diluting existing shareholders.
- Warrant Cancellations: Note that warrants issued in March 2026 to First Finance were cancelled in August 2026 as a condition of the Merger.